Q1 EPS Estimate for Bristol-Myers Squibb Lowered by Analyst

Bristol-Myers Squibb (NYSE:BMY) – Analysts at William Blair reduced their Q1 2025 EPS estimates for Bristol-Myers Squibb in a research report issued to clients and investors on Monday, April 14th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings per share of $1.59 for the quarter, down from their prior forecast of $1.62. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $6.74 per share. William Blair also issued estimates for Bristol-Myers Squibb’s Q3 2025 earnings at $1.79 EPS, Q4 2025 earnings at $1.79 EPS and FY2025 earnings at $6.74 EPS.

A number of other brokerages have also recently commented on BMY. Wells Fargo & Company lifted their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research note on Friday, February 7th. Citigroup upped their price target on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. UBS Group dropped their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research report on Friday, April 11th. The Goldman Sachs Group restated a “neutral” rating and issued a $55.00 price objective (down previously from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Finally, Cantor Fitzgerald raised their target price on Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $57.67.

Bristol-Myers Squibb Stock Down 0.3 %

BMY opened at $49.24 on Wednesday. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The business’s 50-day moving average price is $57.11 and its 200-day moving average price is $56.66. The company has a market cap of $100.18 billion, a P/E ratio of -11.14, a P/E/G ratio of 2.07 and a beta of 0.41.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.04%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -56.11%.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,823 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The shares were acquired at an average price of $54.84 per share, with a total value of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares of the company’s stock, valued at approximately $3,506,030.88. The trade was a 2.94 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.07% of the company’s stock.

Hedge Funds Weigh In On Bristol-Myers Squibb

Several large investors have recently made changes to their positions in BMY. Pinney & Scofield Inc. purchased a new position in Bristol-Myers Squibb during the fourth quarter valued at $25,000. Park Square Financial Group LLC bought a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at $26,000. Fairway Wealth LLC purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter worth about $28,000. Transce3nd LLC bought a new position in Bristol-Myers Squibb in the 4th quarter worth about $28,000. Finally, Global Wealth Strategies & Associates grew its position in Bristol-Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 275 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.